On June 6th, GlobeNewswire announced that I-Mab (IMAB.US) has appointed Dr. Phillip Dennis as chief medical officer. Dr. Phillip Dennis will join I-Mab on June 17th, 2024, leading the company's global clinical development work and serving as a member of I-Mab's executive leadership team.
"I am delighted to welcome Dr. Phillip Dennis as our chief medical officer. Dr. Phillip Dennis has more than 20 years of experience in the field of oncology drug development, including his role as a cross-functional leader of an international team developing a novel PD-L1 inhibitor and his contributions to the development of assets for lung cancer and other cancers. "Rajeev Venkayya, CEO of I-Mab, said," I look forward to working with Dr. Phillip Dennis to further advance our clinical development pipeline and unlock I-Mab's potential for patients and shareholders. ""I am excited to join I-Mab at this critical time in the company's growth," said Dr. Phillip Dennis.
Dr. Phillip Dennis said," I am excited by the opportunity to work on uliledlimab, givastomig and ragistomig, which are based on data from monotherapy and combination therapy in late-stage solid tumors, including lung and gastric cancer, presented so far at major medical conferences. I look forward to working with my outstanding colleagues to support the accelerated development of I-Mab's clinical pipeline."
Prior to joining I-Mab, Dr. Phillip Dennis was Vice President of Lung Cancer Strategy and Global Project Leader for a new and first of its kind ADC at Sanofi (SNY.US). Before joining Sanofi, Dr. Dennis was Vice President of Lung Cancer Strategy and Global Clinical Head at AstraZeneca (NASDAQ: AZN). In these roles, Dr. Dennis served as the disease strategy lead for lung cancer and led cross-functional development of key assets. Prior to his career in the pharmaceutical industry, Dr. Dennis was a professor of oncology, medicine, and pharmacology at Johns Hopkins University and published extensively. Dr. Dennis received his Master's, Doctorate, and Doctor of Medicine degrees from the New York University School of Medicine. He completed internal medicine residency and medical oncology fellowship training at Johns Hopkins. Dr. Dennis also served as a translational researcher at the National Cancer Institute for 14 years and was appointed as a senior investigator. He is an elected member of the American Society of Clinical Investigation and has received numerous awards, including the NIH Outstanding Award.